These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 16637928)
1. The basis for treatment in multiple sclerosis. Compston A Acta Neurol Scand Suppl; 2006; 183():41-7. PubMed ID: 16637928 [TBL] [Abstract][Full Text] [Related]
2. Axonal damage in multiple sclerosis: a complex issue in a complex disease. Grigoriadis N; Ben-Hur T; Karussis D; Milonas I Clin Neurol Neurosurg; 2004 Jun; 106(3):211-7. PubMed ID: 15177770 [TBL] [Abstract][Full Text] [Related]
3. The pathogenesis and basis for treatment in multiple sclerosis. Compston A Clin Neurol Neurosurg; 2004 Jun; 106(3):246-8. PubMed ID: 15177777 [TBL] [Abstract][Full Text] [Related]
4. [Multiple sclerosis: role of growth factors and remyelination]. Lubetzki C Presse Med; 1994 Nov; 23(34):1577-81. PubMed ID: 7824494 [TBL] [Abstract][Full Text] [Related]
5. Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression. Zeydan B; Rodriguez M; Kantarci OH Adv Exp Med Biol; 2017; 958():161-170. PubMed ID: 28093713 [TBL] [Abstract][Full Text] [Related]
6. Remyelination of the central nervous system. Compston A Mult Scler; 1996 Jul; 1(6):388-92. PubMed ID: 9345424 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of axon-glial injury of the optic nerve. Compston A Eye (Lond); 2004 Nov; 18(11):1182-7. PubMed ID: 15534604 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies in multiple sclerosis. II. Long-term repair. Scolding N Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1711-20. PubMed ID: 10603622 [TBL] [Abstract][Full Text] [Related]
14. [Therapeutic perspectives in multiple sclerosis]. Lubetzki C Rev Prat; 2006 Jun; 56(12):1347-52. PubMed ID: 16948223 [TBL] [Abstract][Full Text] [Related]
16. Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection? Dubessy AL; Zujovic V; Papeix C; Stankoff B Rev Neurol (Paris); 2014 Dec; 170(12):770-8. PubMed ID: 25459127 [TBL] [Abstract][Full Text] [Related]
17. Secondary progressive multiple sclerosis: current knowledge and future challenges. Rovaris M; Confavreux C; Furlan R; Kappos L; Comi G; Filippi M Lancet Neurol; 2006 Apr; 5(4):343-54. PubMed ID: 16545751 [TBL] [Abstract][Full Text] [Related]
18. Natural products: Potential therapeutic agents in multiple sclerosis. Yu S; Liu M; Hu K Int Immunopharmacol; 2019 Feb; 67():87-97. PubMed ID: 30537635 [TBL] [Abstract][Full Text] [Related]
19. Remyelination in multiple sclerosis: a new role for neurotrophins? Althaus HH Prog Brain Res; 2004; 146():415-32. PubMed ID: 14699977 [TBL] [Abstract][Full Text] [Related]
20. Demyelination in spinal cord injury and multiple sclerosis: what can we do to enhance functional recovery? Waxman SG J Neurotrauma; 1992 Mar; 9 Suppl 1():S105-17. PubMed ID: 1588601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]